People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | — | Biotechnology | Series D+ | $162.6M | $4.1B | 2018 |
| Semma Therapeutics, Inc. | — | Biotechnology | Series D+ | $129.3M | $4.7B | 2017 |
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $994.9M | 2020 |
| Latigo Biotherapeutics, Inc. | — | Biotechnology | Series C | $50.0M | $357.5M | 2025 |
Kevin Raidy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Raidy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Todd Foley | 1 | 12 |
| Hoyoung Huh | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Jason Hafler | 1 | 6 |
| STEPHEN KNIGHT | 1 | 6 |
| Nancy Stagliano | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Jim Tananbaum | 1 | 4 |
| Charles Homcy | 1 | 4 |
| Kathleen Glaub | 1 | 3 |
| Daniel Auerbach | 1 | 3 |
| Robert Tjian | 1 | 3 |
| Marcus Boehm | 1 | 3 |
| Robert Millman | 1 | 3 |
| Mitchell Finer | 1 | 3 |
| Gayle Crowell | 1 | 3 |
| Deborah Palestrant | 1 | 3 |
| Kathleen Sereda Glaub | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.